These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 25100255

  • 21. Honokiol inhibits osteoclast differentiation and function in vitro.
    Hasegawa S, Yonezawa T, Ahn JY, Cha BY, Teruya T, Takami M, Yagasaki K, Nagai K, Woo JT.
    Biol Pharm Bull; 2010; 33(3):487-92. PubMed ID: 20190414
    [Abstract] [Full Text] [Related]

  • 22. Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 Pathways.
    Wei ZF, Tong B, Xia YF, Lu Q, Chou GX, Wang ZT, Dai Y.
    PLoS One; 2013; 8(3):e59171. PubMed ID: 23536866
    [Abstract] [Full Text] [Related]

  • 23. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.
    Park KH, Gu DR, Jin SH, Yoon CS, Ko W, Kim YC, Lee SH.
    Am J Chin Med; 2017; 45(8):1725-1744. PubMed ID: 29121799
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. (2S)-2'-Methoxykurarinone inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling.
    Kim JY, Kim JY, Kim JJ, Oh J, Kim YC, Lee MS.
    Biol Pharm Bull; 2014; 37(2):255-61. PubMed ID: 24492722
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A novel small molecule, NecroX-7, inhibits osteoclast differentiation by suppressing NF-κB activity and c-Fos expression.
    Kim HJ, Yoon KA, Lee MK, Kim SH, Lee IK, Kim SY.
    Life Sci; 2012 Nov 02; 91(19-20):928-34. PubMed ID: 23000100
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH.
    Mol Pharmacol; 2010 Jan 02; 77(1):17-25. PubMed ID: 19828731
    [Abstract] [Full Text] [Related]

  • 30. GSH attenuates RANKL-induced osteoclast formation in vitro and LPS-induced bone loss in vivo.
    Han B, Geng H, Liu L, Wu Z, Wang Y.
    Biomed Pharmacother; 2020 Aug 02; 128():110305. PubMed ID: 32485573
    [Abstract] [Full Text] [Related]

  • 31. Ginsenoside Rb2 inhibits osteoclast differentiation through nuclear factor-kappaB and signal transducer and activator of transcription protein 3 signaling pathway.
    Cong F, Liu J, Wang C, Yuan Z, Bi L, Liang J, Su K, Qiu Y, Song T, Fan J, Chao G.
    Biomed Pharmacother; 2017 Aug 02; 92():927-934. PubMed ID: 28605877
    [Abstract] [Full Text] [Related]

  • 32. Desoxyrhapontigenin inhibits RANKL‑induced osteoclast formation and prevents inflammation‑mediated bone loss.
    Tran PT, Park DH, Kim O, Kwon SH, Min BS, Lee JH.
    Int J Mol Med; 2018 Jul 02; 42(1):569-578. PubMed ID: 29693149
    [Abstract] [Full Text] [Related]

  • 33. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
    Nakagawa S, Omori K, Nakayama M, Mandai H, Yamamoto S, Kobayashi H, Sako H, Sakaida K, Yoshimura H, Ishii S, Ibaragi S, Hirai K, Yamashiro K, Yamamoto T, Suga S, Takashiba S.
    Int Immunopharmacol; 2020 Jun 02; 83():106429. PubMed ID: 32222639
    [Abstract] [Full Text] [Related]

  • 34. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
    Odkhuu E, Koide N, Haque A, Tsolmongyn B, Naiki Y, Hashimoto S, Komatsu T, Yoshida T, Yokochi T.
    Immunol Lett; 2012 Feb 29; 142(1-2):34-40. PubMed ID: 22193059
    [Abstract] [Full Text] [Related]

  • 35. Specnuezhenide suppresses diabetes-induced bone loss by inhibiting RANKL-induced osteoclastogenesis.
    Ye X, Jiang J, Yang J, Yan W, Jiang L, Chen Y.
    Acta Biochim Biophys Sin (Shanghai); 2022 Aug 25; 54(8):1080-1089. PubMed ID: 35929595
    [Abstract] [Full Text] [Related]

  • 36. Decursin from Angelica gigas suppresses RANKL-induced osteoclast formation and bone loss.
    Wang X, Zheng T, Kang JH, Li H, Cho H, Jeon R, Ryu JH, Yim M.
    Eur J Pharmacol; 2016 Mar 05; 774():34-42. PubMed ID: 26825541
    [Abstract] [Full Text] [Related]

  • 37. Ethanol extract of Cyathulae Radix inhibits osteoclast differentiation and bone loss.
    Shi L, Ren L, Li J, Liu X, Lu J, Jia L, Xie B, Tang S, Liu W, Zhang J.
    Chin J Nat Med; 2024 Mar 05; 22(3):212-223. PubMed ID: 38553189
    [Abstract] [Full Text] [Related]

  • 38. The Effects of Aronia melanocarpa 'Viking' Extracts in Attenuating RANKL-Induced Osteoclastic Differentiation by Inhibiting ROS Generation and c-FOS/NFATc1 Signaling.
    Ghosh M, Kim IS, Lee YM, Hong SM, Lee TH, Lim JH, Debnath T, Lim BO.
    Molecules; 2018 Mar 08; 23(3):. PubMed ID: 29518052
    [Abstract] [Full Text] [Related]

  • 39. Oleanolic acid acetate inhibits osteoclast differentiation by downregulating PLCγ2-Ca(2+)-NFATc1 signaling, and suppresses bone loss in mice.
    Kim JY, Cheon YH, Oh HM, Rho MC, Erkhembaatar M, Kim MS, Lee CH, Kim JJ, Choi MK, Yoon KH, Lee MS, Oh J.
    Bone; 2014 Mar 08; 60():104-11. PubMed ID: 24361669
    [Abstract] [Full Text] [Related]

  • 40. 9-Hydroxy-6,7-dimethoxydalbergiquinol inhibits osteoclast differentiation through down-regulation of Akt, c-Fos and NFATc1.
    Kim JY, Kim JY, Cheon YH, Kwak SC, Baek JM, Kim YC, Yoon KH, Oh J, Lee MS.
    Int Immunopharmacol; 2014 May 08; 20(1):213-20. PubMed ID: 24630975
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.